AIM VACCINE (06660) has released its interim results for the six months ended June 30, 2026, reporting revenue of RMB351 million. The company recorded a loss attributable to owners of the parent of RMB123 million, with a loss per share of RMB0.1.
During 2025, the company achieved significant milestones in international market penetration. Its quadrivalent meningococcal polysaccharide vaccine successfully entered the African market, the rabies vaccine made its first foray into Central America, and the hepatitis B vaccine achieved its inaugural export. In the first half of 2026, the company initiated six new registration projects covering hepatitis B, hepatitis A, and meningococcal vaccines across three countries in Southeast Asia, South Asia, and Africa.
Registration activities for the hepatitis B vaccine are actively progressing in Southeast Asia, potentially offering a new preventive option for local populations. The hepatitis A vaccine registration is proceeding in an orderly manner in South Asia, aimed at enhancing regional hepatitis A prevention capabilities. Concurrently, the MPSV4 vaccine is steadily advancing through registration in Central Asia, with expectations for local market launch next year.
The company is also dedicating substantial efforts to prepare for the international commercialization of its upcoming iterative pneumonia vaccine and serum-free iterative rabies vaccine. Exclusive agency agreements have been established with multiple countries in West Asia and Southeast Asia, creating pathways for product entry into these markets. Additionally, AIM VACCINE has formally signed a memorandum of understanding with Egypt for the iterative pneumonia vaccine, further expanding its footprint in the Middle East and North Africa region and laying a solid foundation for future sales growth. These achievements underscore the company's robust market expansion capabilities and signal its increasingly significant role in the global vaccine landscape.
In terms of research and development, the company is aligning its product pipeline with international market demand. According to the latest World Health Organization vaccine prequalification list (2024–2026), the iterative pneumonia vaccine and quadrivalent conjugate meningococcal vaccine currently under rapid development are both classified as high-priority prequalified products. Furthermore, the respiratory syncytial virus vaccine and shingles vaccine being actively developed are also internationally scarce vaccine varieties. The company is diligently working to advance domestic and international registration and sales of these products, while pursuing WHO prequalification for its vaccines.
Among its marketed products, the hepatitis A vaccine, hepatitis B vaccine, and rabies vaccine are all WHO high-priority prequalified products that are well-received in international markets. The company has successively launched a series of full-chain temperature monitoring products to ensure vaccine safety and efficacy, covering freeze-dried human rabies vaccine (Vero cells), recombinant hepatitis B vaccine (Hansenula polymorpha), ACYW135 meningococcal polysaccharide vaccine (MPSV4), and inactivated hepatitis A vaccine (human diploid cells). These offerings cater to diverse customer requirements, provide multiple specifications, and enhance vaccine temperature control and identification, further upgrading vaccine quality management and improving market competitiveness.
Regarding production capacity, GMP workshops for the iterative pneumonia vaccine series and iterative rabies vaccine series have been completed in phases, meeting international standards. Phase III clinical samples and process validation samples for the serum-free iterative rabies vaccine, high-titer human diploid rabies vaccine, 23-valent pneumococcal polysaccharide vaccine, and 13-valent pneumococcal conjugate vaccine are all produced in these facilities, ensuring readiness for rapid overseas expansion following product launches.
In the second half of 2026, AIM VACCINE will continue to accelerate the commercialization and market warming efforts for major products such as the iterative rabies vaccine series. The company aims to deepen cooperation ties with Belt and Road Initiative countries, bringing quality vaccines to underserved global medical needs. Leveraging its proprietary mRNA technology platform as a driving force, the company will break through development barriers for internationally scarce vaccines including respiratory syncytial virus and shingles vaccines. With intelligent production capacity and comprehensive cold chain systems, it will solidify its global competitiveness in quality and supply, remaining committed to its mission of manufacturing conscientious vaccines for the health of people worldwide.